Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 16Recruiting 5Terminated 4Unknown 3Not yet recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 38Carcinoma, Hepatocellular 14Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Stomach Neoplasms 3Recurrence 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Glioblastoma 3Diabetes Mellitus, Insulin-Dependent, 12 2Brain Neoplasms 2mCRC 1Uterine Cervical Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rectal Neoplasms Malignant 1Proteinuria 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-resistant Recurrent Ovarian Cancer (PROC) 1Platinum-resistant Recurrent Ovarian Cancer 1Osteosarcoma 1Non-small Cell Lung Cancer Patients with Brain Metastases 1Neutropenia 1Neoplastic Cells, Circulating 1NSCLC 1Metastatic Colorectal Cancer With Left-sided Primary Tumor 1Medulloblastoma 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Bevacizumab × Clear all
NCT06041490 2023-09-18

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
88 enrolled
GastrointestinalSarcoma

Carcinoma, Hepatocellular, Recurrence, Osteosarcoma

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
368 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡